Work

K41-A enhances the antiproliferative efficacy of cisplatin in neuroblastoma by modulating apoptosis and autophagy

Year: 2025

Type: article

Abstract: OBJECTIVES: Neuroblastoma (NB), the most common extracranial tumor in childhood, has a poor prognosis, especially in cases with MYC gene amplification. Cisplatin (CDDP) is widely used in treatment, but its effectiveness is limited due to chemotherapy resistance. Autophagy plays a dual role in cancer progression, either promoting survival or contributing to cell death. METHODS: This study explores the anticancer effects of K41-A, a polycyclic polyether molecule, alone and in combination with CDDP in SH-SY5Y and KELLY NB cell lines, the HE-IOC1 noncancerous cochlear cell line, and the NB xenograft model. KEY FINDINGS: For the first time, we demonstrate that K41-A, either alone or combined with CDDP, significantly inhibits cell proliferation selectively in NB cells, sparing noncancerous cells. This study confirmed that K41-A alone and in combination with CDDP induced changes in both apoptotic and autophagic cell death components in NB, resulting in antiproliferative activity in vitro and in vivo. In addition, the combination with CDDP enhanced the therapeutic efficacy of K41-A. CONCLUSIONS: These results highlight the potential of K41-A as a candidate drug for the treatment of NB.

Source: Journal of Pharmacy and Pharmacology

DOI: 10.1093/jpp/rgaf131

Authors: Gamze Sanlav, Selen Kum Ozsengezer, Zekiye Altun, Erdal Bedir, Safiye Aktas, Nur Olgun

Institutions: Dokuz Eylül University, Izmir Institute of Technology

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,839